BRANIMIR I. SIKIC, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA

License number

California G41273

Professional information

Dr. Branimir I Sikic, Palo Alto CA - MD (Doctor of Medicine)

Specialties:

Oncology, Medical Oncology

Address:

Stanford Comp Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
(650) 498-6000 (Phone)

Certifications:

Internal Medicine, 1975, Medical Oncology, 1979

Awards:

Healthgrades Honor Roll

Languages:

English, Spanish

Hospitals:

Stanford Comp Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
Menlo Park Surgical Hospital
570 Willow Rd, Menlo Park 94025
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305

Education:

Medical School
Rosalind Franklin University Of Medicine Science/The Chicago Medical School
Graduated: 1972
Georgetown University Hospital
Graduated: 1973
Graduated: 1975
Graduated: 1979

Branimir Ivan Sikic, Palo Alto CA

Specialties:

Internal Medicine, Medical Oncology, Hematology & Oncology

Work:

Medical Oncology
875 Blake Wilbur Dr, Palo Alto, CA 94304 Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304

Education:

University of Chicago (1972)

P-Glycoprotein Mutant Resistant To Cyclosporin Modulation

US Patent:

5830697, Nov 3, 1998

Filed:

Jan 21, 1997

Appl. No.:

8/784649

Inventors:

Branimir I. Sikic - Stanford CA
Gang Chen - Palo Alto CA

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12P 2106, C12N 522, C12N 1512, C07K 14435

US Classification:

435 691

Abstract:

A mutated form of human P-glycoprotein (mdr1. DELTA. F335/336) is identified, consisting of a single or double codon deletion (Phe335 and/or 336) in the TM region of P-gp. The mdr1. DELTA. F335/336 encoded P-glycoprotein is characterized by an altered spectrum of cross-reactivity to cytotoxins and resistance to modulation by cyclosporins, with a loss of the capacity to bind or transport cyclosporine, PSC 833, and vinblastine. These data demonstrate that cyclosporine, PSC 833, vinblastine, Rh-123, and dactinomycin share at least one binding domain on, which plays an important role in the interaction of P-gp with modulators. The nucleic acid compositions encoding mdr1. DELTA. F335/336 find use in gene therapy to transfer modulator-resistant multidrug resistance into transfected cells; to produce the encoded protein for functional mapping studies, and in studying associated physiological pathways.

Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism

US Patent:

2007000, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/417984

Inventors:

Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 39/395, A61K 38/13, A61K 31/553, A61K 31/551, A61K 31/455, A61K 31/4709, A61K 31/704, A61K 31/277, A61K 31/138

US Classification:

424155100, 514220000, 514011000, 514026000, 514263320, 514317000, 514469000, 514253040, 514389000, 514291000, 514225800, 514314000, 514355000, 514211070, 514521000, 514651000

Abstract:

The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.

Protein Modulators Of Resistance To Alkylating Agents

US Patent:

7875274, Jan 25, 2011

Filed:

Dec 13, 2006

Appl. No.:

11/638161

Inventors:

Branimir Sikic - Stanford CA, US
Markus Bredel - Evanston IL, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 48/00, C12Q 1/68

US Classification:

424 9321, 435 6, 977802

Abstract:

There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e. g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with an alkylating agent. The method is directed to the NF-κB activation in response to DNA damage caused by alkylating agents. It comprises the step of measuring a level of expression of a protein, which participates in the NF-κB pathway. Preferably it comprises measuring the expression of TNFAIP3 in the cell, wherein a resistant phenotype has less expression of TNFAIP3 than a sensitive phenotype. Another particularly significant gene, which predicts survival, is NFKBIA. Other genes whose altered expression level is associated with resistance or prognosis are TNIP1, TNIP2, RIP, NFKBIB, Beta4GalNAc-T4, NFKBIE, C8orf4, LIF, CD44, FBXO32, and SDC1, and these are also measured in certain embodiments.

Chemotherapeutic Formulations Of Zosuquidar Trihydrochloride And Modified Cyclodextrins

US Patent:

2007001, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/418400

Inventors:

Jeff Schwegman - Bloomington IN, US
Mark Edgar - Rancho Santa Fe CA, US
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US

International Classification:

A61K 31/724

US Classification:

514058000

Abstract:

The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination with a modified cyclodextrin.

Treatment Of Patients With Cancer Using A Calicheamicin-Antibody Conjugate In Combination With Zosuquidar

US Patent:

2007000, Jan 11, 2007

Filed:

May 3, 2006

Appl. No.:

11/416992

Inventors:

International Classification:

A61K 39/395, A61K 31/4709

US Classification:

424155100, 424178100, 514314000

Abstract:

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.